Company intelligence / Profile preview

RootPath

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

RootPath’s technology platform enables massively parallel synthesis and functional screening of T cell receptor (TCR) genes, demonstrating successful identification of tumor-reactive TCRs and functional synthetic TILs in pre-clinical research targeting solid tumors. The technology was validated in studies published in Nature Biotechnology and Nature Medicine, with commercial synthesis and screening services launching.

Therapeutic areas: OncologyImmunology
Modalities: Gene therapyT cell receptor engineered T cell therapyCell therapySynthetic gene synthesis
Industry: Biotech

Partnerships

Netherlands Cancer Institute (NKI)

Beyond the preview

Go deeper on RootPath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RootPath.

Explore the full profile